These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 26854906)

  • 21. Immunogenicity of the tuberculosis vaccine MVA85A is reduced by coadministration with EPI vaccines in a randomized controlled trial in Gambian infants.
    Ota MO; Odutola AA; Owiafe PK; Donkor S; Owolabi OA; Brittain NJ; Williams N; Rowland-Jones S; Hill AV; Adegbola RA; McShane H
    Sci Transl Med; 2011 Jun; 3(88):88ra56. PubMed ID: 21697532
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The candidate tuberculosis vaccine Mtb72F/AS02 in PPD positive adults: a randomized controlled phase I/II study.
    Spertini F; Audran R; Lurati F; Ofori-Anyinam O; Zysset F; Vandepapelière P; Moris P; Demoitié MA; Mettens P; Vinals C; Vastiau I; Jongert E; Cohen J; Ballou WR
    Tuberculosis (Edinb); 2013 Mar; 93(2):179-88. PubMed ID: 23219236
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A double-blind, randomised, placebo-controlled, dose-finding trial of the novel tuberculosis vaccine AERAS-402, an adenovirus-vectored fusion protein, in healthy, BCG-vaccinated infants.
    Tameris M; Hokey DA; Nduba V; Sacarlal J; Laher F; Kiringa G; Gondo K; Lazarus EM; Gray GE; Nachman S; Mahomed H; Downing K; Abel B; Scriba TJ; McClain JB; Pau MG; Hendriks J; Dheenadhayalan V; Ishmukhamedov S; Luabeya AK; Geldenhuys H; Shepherd B; Blatner G; Cardenas V; Walker R; Hanekom WA; Sadoff J; Douoguih M; Barker L; Hatherill M
    Vaccine; 2015 Jun; 33(25):2944-54. PubMed ID: 25936724
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and immunogenicity of an inactivated whole cell tuberculosis vaccine booster in adults primed with BCG: A randomized, controlled trial of DAR-901.
    von Reyn CF; Lahey T; Arbeit RD; Landry B; Kailani L; Adams LV; Haynes BC; Mackenzie T; Wieland-Alter W; Connor RI; Tvaroha S; Hokey DA; Ginsberg AM; Waddell R
    PLoS One; 2017; 12(5):e0175215. PubMed ID: 28498853
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ag85B-ESAT-6 adjuvanted with IC31® promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in volunteers with previous BCG vaccination or tuberculosis infection.
    van Dissel JT; Soonawala D; Joosten SA; Prins C; Arend SM; Bang P; Tingskov PN; Lingnau K; Nouta J; Hoff ST; Rosenkrands I; Kromann I; Ottenhoff TH; Doherty TM; Andersen P
    Vaccine; 2011 Mar; 29(11):2100-9. PubMed ID: 21256189
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Process of assay selection and optimization for the study of case and control samples from a phase IIb efficacy trial of a candidate tuberculosis vaccine, MVA85A.
    Harris SA; Satti I; Matsumiya M; Stockdale L; Chomka A; Tanner R; O'Shea MK; Manjaly Thomas ZR; Tameris M; Mahomed H; Scriba TJ; Hanekom WA; Fletcher HA; McShane H
    Clin Vaccine Immunol; 2014 Jul; 21(7):1005-11. PubMed ID: 24828094
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and immunogenicity of the novel tuberculosis vaccine ID93 + GLA-SE in BCG-vaccinated healthy adults in South Africa: a randomised, double-blind, placebo-controlled phase 1 trial.
    Penn-Nicholson A; Tameris M; Smit E; Day TA; Musvosvi M; Jayashankar L; Vergara J; Mabwe S; Bilek N; Geldenhuys H; Luabeya AK; Ellis R; Ginsberg AM; Hanekom WA; Reed SG; Coler RN; Scriba TJ; Hatherill M;
    Lancet Respir Med; 2018 Apr; 6(4):287-298. PubMed ID: 29595510
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adenovirus type 35-vectored tuberculosis vaccine has an acceptable safety and tolerability profile in healthy, BCG-vaccinated, QuantiFERON(®)-TB Gold (+) Kenyan adults without evidence of tuberculosis.
    Walsh DS; Owira V; Polhemus M; Otieno L; Andagalu B; Ogutu B; Waitumbi J; Hawkridge A; Shepherd B; Pau MG; Sadoff J; Douoguih M; McClain JB;
    Vaccine; 2016 May; 34(21):2430-2436. PubMed ID: 27026148
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in Mycobacterium tuberculosis-infected individuals.
    Sander CR; Pathan AA; Beveridge NE; Poulton I; Minassian A; Alder N; Van Wijgerden J; Hill AV; Gleeson FV; Davies RJ; Pasvol G; McShane H
    Am J Respir Crit Care Med; 2009 Apr; 179(8):724-33. PubMed ID: 19151191
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase IIa trial of the new tuberculosis vaccine, MVA85A, in HIV- and/or Mycobacterium tuberculosis-infected adults.
    Scriba TJ; Tameris M; Smit E; van der Merwe L; Hughes EJ; Kadira B; Mauff K; Moyo S; Brittain N; Lawrie A; Mulenga H; de Kock M; Makhethe L; Janse van Rensburg E; Gelderbloem S; Veldsman A; Hatherill M; Geldenhuys H; Hill AV; Hawkridge A; Hussey GD; Hanekom WA; McShane H; Mahomed H
    Am J Respir Crit Care Med; 2012 Apr; 185(7):769-78. PubMed ID: 22281831
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Improved CD4⁺ T cell responses to Mycobacterium tuberculosis in PPD-negative adults by M72/AS01 as compared to the M72/AS02 and Mtb72F/AS02 tuberculosis candidate vaccine formulations: a randomized trial.
    Leroux-Roels I; Forgus S; De Boever F; Clement F; Demoitié MA; Mettens P; Moris P; Ledent E; Leroux-Roels G; Ofori-Anyinam O;
    Vaccine; 2013 Apr; 31(17):2196-206. PubMed ID: 22643213
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The safety and immunogenicity of an adenovirus type 35-vectored TB vaccine in HIV-infected, BCG-vaccinated adults with CD4(+) T cell counts >350 cells/mm(3).
    Churchyard GJ; Snowden MA; Hokey D; Dheenadhayalan V; McClain JB; Douoguih M; Pau MG; Sadoff J; Landry B
    Vaccine; 2015 Apr; 33(15):1890-6. PubMed ID: 25698492
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The novel tuberculosis vaccine, AERAS-402, is safe in healthy infants previously vaccinated with BCG, and induces dose-dependent CD4 and CD8T cell responses.
    Kagina BM; Tameris MD; Geldenhuys H; Hatherill M; Abel B; Hussey GD; Scriba TJ; Mahomed H; Sadoff JC; Hanekom WA; ; Mansoor N; Hughes J; de Kock M; Whatney W; Africa H; Krohn C; Veldsman A; Kany AL; Douoguih M; Pau MG; Hendriks J; McClainc B; Benko J; Snowden MA; Hokey DA
    Vaccine; 2014 Oct; 32(45):5908-17. PubMed ID: 25218194
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and immunogenicity of the candidate tuberculosis vaccine MVA85A in West Africa.
    Brookes RH; Hill PC; Owiafe PK; Ibanga HB; Jeffries DJ; Donkor SA; Fletcher HA; Hammond AS; Lienhardt C; Adegbola RA; McShane H; Hill AV
    PLoS One; 2008 Aug; 3(8):e2921. PubMed ID: 18698342
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Systematic Review and Meta-Analysis on the Immunogenicity and Safety of the Tuberculosis Subunit Vaccines M72/AS01
    Ullah I; Bibi S; Ul Haq I; Safia ; Ullah K; Ge L; Shi X; Bin M; Niu H; Tian J; Zhu B
    Front Immunol; 2020; 11():1806. PubMed ID: 33133057
    [No Abstract]   [Full Text] [Related]  

  • 36. Safety and immunogenicity of the novel H4:IC31 tuberculosis vaccine candidate in BCG-vaccinated adults: Two phase I dose escalation trials.
    Norrby M; Vesikari T; Lindqvist L; Maeurer M; Ahmed R; Mahdavifar S; Bennett S; McClain JB; Shepherd BM; Li D; Hokey DA; Kromann I; Hoff ST; Andersen P; de Visser AW; Joosten SA; Ottenhoff THM; Andersson J; Brighenti S
    Vaccine; 2017 Mar; 35(12):1652-1661. PubMed ID: 28216183
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and immunogenicity of the M72/AS01 candidate tuberculosis vaccine when given as a booster to BCG in Gambian infants: an open-label randomized controlled trial.
    Idoko OT; Owolabi OA; Owiafe PK; Moris P; Odutola A; Bollaerts A; Ogundare E; Jongert E; Demoitié MA; Ofori-Anyinam O; Ota MO
    Tuberculosis (Edinb); 2014 Dec; 94(6):564-78. PubMed ID: 25305000
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Boosting BCG with recombinant modified vaccinia ankara expressing antigen 85A: different boosting intervals and implications for efficacy trials.
    Pathan AA; Sander CR; Fletcher HA; Poulton I; Alder NC; Beveridge NE; Whelan KT; Hill AV; McShane H
    PLoS One; 2007 Oct; 2(10):e1052. PubMed ID: 17957238
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Modified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells.
    Scriba TJ; Tameris M; Mansoor N; Smit E; van der Merwe L; Isaacs F; Keyser A; Moyo S; Brittain N; Lawrie A; Gelderbloem S; Veldsman A; Hatherill M; Hawkridge A; Hill AV; Hussey GD; Mahomed H; McShane H; Hanekom WA
    Eur J Immunol; 2010 Jan; 40(1):279-90. PubMed ID: 20017188
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Two doses of candidate TB vaccine MVA85A in antiretroviral therapy (ART) naïve subjects gives comparable immunogenicity to one dose in ART+ subjects.
    Dieye TN; Ndiaye BP; Dieng AB; Fall M; Brittain N; Vermaak S; Camara M; Diop-Ndiaye H; Ngom-Gueye NF; Diaw PA; Toure-Kane C; Sow PS; Mboup S; McShane H
    PLoS One; 2013; 8(6):e67177. PubMed ID: 23840618
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.